Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe
暂无分享,去创建一个
Mithat Gönen | John Humm | Steven M. Larson | Yunpeng Ye | H. William Strauss | Evan Phillips | Heiko Schöder | Ulrich Wiesner | Pauliah Mohan | J. Humm | S. Larson | M. Gönen | R. Carvajal | H. Kalaigian | H. Strauss | H. Schöder | Ulrich B Wiesner | Y. Ye | P. Zanzonico | Oula Penate-Medina | Oula Peñate-Medina | M. Bradbury | Evan Phillips | Pauliah Mohan | Hovanes Kalaigian | Pat B. Zanzonico | Michelle S. Bradbury | Richard D. Carvajal
[1] Jesse V Jokerst,et al. Molecular imaging with theranostic nanoparticles. , 2011, Accounts of chemical research.
[2] Mark E. Davis,et al. Targeting kidney mesangium by nanoparticles of defined size , 2011, Proceedings of the National Academy of Sciences.
[3] B. Wolffenbuttel,et al. The diagnostic value of 124I-PET in patients with differentiated thyroid cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[4] A. Vahrmeijer,et al. Optical Image-Guided Cancer Surgery: Challenges and Limitations , 2013, Clinical Cancer Research.
[5] Daniel A. Heller,et al. Treating metastatic cancer with nanotechnology , 2011, Nature Reviews Cancer.
[6] D. Koutras,et al. Iodine kinetics in man--a model. , 1968, Journal of Clinical Endocrinology and Metabolism.
[7] J. Frangioni,et al. Image-Guided Surgery Using Invisible Near-Infrared Light: Fundamentals of Clinical Translation , 2010, Molecular imaging.
[8] A. Wunder,et al. Albumin-based drug carriers: comparison between serum albumins of different species on pharmacokinetics and tumor uptake of the conjugate. , 1999, Anti-cancer drugs.
[9] Daniel K. Bonner,et al. Large stokes-shift fluorescent silica nanoparticles with enhanced emission over free dye for single excitation multiplexing. , 2009, Macromolecular rapid communications.
[10] Xiaoyuan Chen,et al. Nanotheranostics for personalized medicine , 2013, Expert review of molecular diagnostics.
[11] A. Aurengo,et al. Iodine kinetics and effectiveness of stable iodine prophylaxis after intake of radioactive iodine: a review. , 2001, Thyroid : official journal of the American Thyroid Association.
[12] Mark B. Carter,et al. Erratum: The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers (Nature Materials (2011) 10 (389-397)) , 2011 .
[13] P. Kubes. Introduction: The complexities of leukocyte recruitment , 2002 .
[14] P. Kubes. The complexities of leukocyte recruitment. , 2002, Seminars in immunology.
[15] I. Buvat,et al. Partial-Volume Effect in PET Tumor Imaging* , 2007, Journal of Nuclear Medicine.
[16] Herbert Malamud,et al. MIRD Primer for Absorbed Dose Calculations , 1989 .
[17] Srikanth K. Iyer,et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. , 2011, The Journal of clinical investigation.
[18] J. Bonventre. Molecular response to cytotoxic injury: role of inflammation, MAP kinases, and endoplasmic reticulum stress response. , 2003, Seminars in nephrology.
[19] Michelle Bradbury,et al. Fluorescent silica nanoparticles with efficient urinary excretion for nanomedicine. , 2009, Nano letters.
[20] R. Duncan. The dawning era of polymer therapeutics , 2003, Nature Reviews Drug Discovery.
[21] M. Schwaiger,et al. Synthesis and biological evaluation of a 99mTc-labelled cyclic RGD peptide for imaging the αvβ3 expression , 2004, Nuklearmedizin.
[22] Zhen Cheng,et al. Near-infrared fluorescent nanoprobes for cancer molecular imaging: status and challenges. , 2010, Trends in molecular medicine.
[23] Robert Jones,et al. A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake , 2005, Clinical Cancer Research.
[24] F. Peillon,et al. Adenomatous transformation of the human anterior pituitary is associated with alterations in integrin expression , 1996, International journal of cancer.
[25] S. Larson,et al. The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development , 2005, Clinical Cancer Research.
[26] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[27] D. Rasmussen,et al. Alcoholic Solvent Effect on Silica Synthesis—NMR and DLS Investigation , 1998 .
[28] Gabor Grothendieck,et al. Lattice: Multivariate Data Visualization with R , 2008 .
[29] Thomas F. Budinger,et al. MIRD primer for absorbed dose calculations , 1988 .
[30] Charles F. Zukoski,et al. Preparation of monodisperse silica particles: control of size and mass fraction , 1988 .
[31] Vladimir Torchilin,et al. Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance , 2012, Clinical Cancer Research.
[32] R. Wilder,et al. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases , 2002, Annals of the rheumatic diseases.
[33] Omid C Farokhzad,et al. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. , 2012, Chemical Society reviews.
[34] Evan Phillips,et al. Clinically-translated silica nanoparticles as dual-modality cancer-targeted probes for image-guided surgery and interventions. , 2012, Integrative biology : quantitative biosciences from nano to macro.
[35] Cecilia Sahlgren,et al. Nanoparticles in targeted cancer therapy: mesoporous silica nanoparticles entering preclinical development stage. , 2012, Nanomedicine.
[36] Sonke Svenson,et al. Theranostics: are we there yet? , 2013, Molecular pharmaceutics.
[37] Horst Kessler,et al. Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD , 2005, PLoS medicine.
[38] R. Jain,et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.
[39] P. Zanzonico,et al. Age-dependent thyroid absorbed doses for radiobiologically significant radioisotopes of iodine. , 2000, Health physics.
[40] Rob J Hyndman,et al. Sample Quantiles in Statistical Packages , 1996 .
[41] M. Taillard. Challenges and Limitations , 2014 .
[42] R. Weissleder,et al. Imaging in the era of molecular oncology , 2008, Nature.
[43] Rhona A. Berganos,et al. Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels. , 2011, Radiology.
[44] Robert C. Wolpert,et al. A Review of the , 1985 .
[45] Ahmed A. Heikal,et al. Silica Nanoparticle Architecture Determines Radiative Properties of Encapsulated Fluorophores , 2008 .
[46] Ulrich Simon,et al. Molecularly stabilised ultrasmall gold nanoparticles: synthesis, characterization and bioactivity. , 2013, Nanoscale.
[47] D. Scheinberg,et al. Conscripts of the infinite armada: systemic cancer therapy using nanomaterials , 2010, Nature Reviews Clinical Oncology.
[48] K. Harrington,et al. The Biodistribution and Pharmacokinetics of Stealth Liposomes in Patients with Solid Tumors , 1997 .
[49] N. E. Schlotter,et al. Correction to “Preparation of monodisperse silica particles: Control of size and mass fraction” by G.H. Bogush, M.A. Tracy and C.F. Zukoski IV, Journal of Non-Crystalline Solids 104 (1988) 95–106 , 2007 .
[50] Juan L. Vivero-Escoto,et al. Silica‐Based Nanoprobes for Biomedical Imaging and Theranostic Applications , 2012 .
[51] Hooisweng Ow,et al. Bright and stable core-shell fluorescent silica nanoparticles. , 2005, Nano letters.